Mark Labrecque Email & Phone Number

Boston, Ma, Us

Boston, Ma, Us

Paris, Île-De-France, Fr

Ultra Rare Disease - Business Development - Genetics - Hepatology - Gastroenterology

San Diego, California, Us

Bile Acid Portfolio Acquired by Mirum Pharmaceuticals from Travere Therapeutics in September 2023. Deliver life changing therapies to children and adults living with ultra rare diseases. Covering all of New England and New York. Focus on large institutions and academic centers. Genetic testing and results interpretation. Calling on Pediatric Hepatology-Gastroenterology, Neonatology, Pediatric Ophthalmology, Adult/Pediatric Genetics, Adult/Pediatric Neurology, Hospital pharmacy and Laboratory.

Boston, Massachusetts, Us

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life threatening diseases often have no effective treatment options, and they and there families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. Synageva become part of Alexion in June of 2015 - I currently work throughout New England with academic institutions and various specialists (Pediatric and Adult Hepatology, Lipidology, Genetics, Gastroenterology, Endocrinology, Pathology, Lysosomal Storage Disease centers, and Metabolic Bone Specialists) to help them identify and diagnose patients and families suffering from Lysosomal Acid Lipase Deficiency (LAL-D) and Hypophosphatasia (HPP).Responsible for the sales of Kanuma and Strensiq: both ultra orhan enzyme replacement therapies.

Lexington, Massachusetts, Us

Synageva is a start-up biopharmaceutical company dedicated to discovering, developing, and delivering medicines for patients with rare diseases and high unmet medical needs. We are passionate about our commitment to improving the lives of patients for generations to come and believe that every patient deserves a treatment option, no matter how rare their disease.Territory included all of New England, NY (NYC and Upstate) and NJ. Responsible for all pre-commercial activities including territory development, KOL initiatives, research and testing projects, and disease awareness and education in Lysosomal Acid Lipase Deficiency (LAL-D), an ultra rare genetic condition characterized by decreased LAL enzyme activity in the lysosomes across multiple body tissues leading to the build up of fatty material in the liver, blood vessels and other tissues. LAL-D is fatal when presenting in infants and leads to significant morbidity and early mortality in children and adults.Synageva was acquired by Alexion in June of 2015.

Boulogne Billancourt, Fr

2011 "Circle of Excellence" winner (TOP 2 in the country). 2011 Growth Club Winner (largest percentage growth year over year). Biotechnology Sales Specialist covering the six New England states. Responsibilities include calling on Neuro-Endocrinology and Hospital pharmacies at major teaching institutions in Boston and throughout New England. Rare growth diseases (Acromegaly and Severe Primary IGF-1 Deficiency) was my primary focus. Responsibilities were patient identification and the sales of 2 pharmaceuticals in a complicated reimbursement arena.

Louisville, Co, Us

Sold Supply Chain Management software and consulting services to hospitals. Accounts utilized company for: supply chain automation, sales force performance enhancement, rebate and claim management, market share reporting, and business intelligence. At the core of all services is the internet trading exchange (open to all members of the healthcare supply chain) including: hospitals, suppliers, distributors, and group purchasing organizations (GPO’s).

Minneapolis, Mn, Us

Successfully sold “Continuous Subcutaneous Insulin Infusion” (insulin pumps) and Continuous Glucose Monitoring systems. Aggressively developed an underperforming territory into a leading territory in the nation, while taking on a leadership role within the Northeast region. Achievements include:Exceptional Achiever Award for FY ’07 (Top 10% out of TM's in the USA).FY ‘07: ranked #6 to quota (161% to plan), #2 with 108.5% revenue of prior year (double prior year’s results).Brought territory from #146 to #15 while exceeding revenue goal by over $700,000.00 (+ 161% to plan).Hard Charger Award Q2 for Northeast region.(Mentored Alex Koslowsky to achieve "IPS of the year").Changed 393 lives of patients and brought in 539 opportunities (goal was 245 and 321 respectively). Sold 393 pumps in FY ‘07 (original goal was 245!).

Successfully managed business development activities for both existing and new hospital accounts selling; Gamma Interferon, Alpha Interferon, and Amphotec. Sold to: Gastroenterology, Pulmonary, Critical Care, Hepatology, Infectious Disease, and Oncology. Developed key opinion leaders, product champions, and speakers for company products. Assisted in the hiring and training of new sales representatives. Achievements included:Finished 2002 ranked #9 overall.Increased territory sales of Actimmune from $1.6M to $1.9M in 2003 and from $624,000 to $1.6M in 2002.Ranked #12 nationally (out of 86) for Infergen and #4 for Amphotec in 2003. Ranked #15 for Amphotec and #39 for Infergen in 2002.Appointed to Marketing Advisory Panel Specialist by Sales Director in 2003 (Northeast Region). Developed selling strategies for indications within managed markets, specialty pharmacy, and Orphan Drug market.

Sold pharmaceuticals into Pulmonary, Allergy, and Primary care. Trained new representatives.Achievements included:Finished 2000 ranked #4 overall (President’s Club Winner).Achieved quotas of 121%, 111%, and 102% for product portfolio in the year 2000.Increased territory sales from $1.2 million to $1.7 million in 1999 and from $671,500 to $1.2 million in 1998.Worked in a District that finished 2nd in 1998 President’s Club (57 National Districts).Attained top 12 positioning for launch of flagship product in 1998 (over 100% of quota).